Spero Therapeutics, Inc.
SPRO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $47,977 | $103,781 | $48,579 | $3,070 |
| % Growth | -53.8% | 113.6% | 1,482.4% | – |
| Cost of Goods Sold | $96,757 | $51,440 | $0 | $0 |
| Gross Profit | -$48,780 | $52,341 | $48,579 | $3,070 |
| % Margin | -101.7% | 50.4% | 100% | 100% |
| R&D Expenses | $96,757 | $51,440 | $47,593 | $64,526 |
| G&A Expenses | $22,912 | $24,988 | $36,483 | $41,701 |
| SG&A Expenses | $23,704 | $25,554 | $36,483 | $41,701 |
| Sales & Mktg Exp. | $792 | $566 | $0 | $0 |
| Other Operating Expenses | -$95,880 | -$46,134 | $6,700 | -$15,186 |
| Operating Expenses | $24,581 | $30,860 | $90,776 | $91,041 |
| Operating Income | -$73,361 | $21,481 | -$42,197 | -$87,971 |
| % Margin | -152.9% | 20.7% | -86.9% | -2,865.5% |
| Other Income/Exp. Net | $4,795 | $3,923 | -$4,218 | -$1,785 |
| Pre-Tax Income | -$68,566 | $25,404 | -$46,415 | -$89,756 |
| Tax Expense | $0 | $2,598 | $0 | $0 |
| Net Income | -$68,566 | $22,806 | -$46,415 | -$89,756 |
| % Margin | -142.9% | 22% | -95.5% | -2,923.6% |
| EPS | -1.27 | 0.43 | -1.23 | -2.91 |
| % Growth | -395.3% | 135% | 57.7% | – |
| EPS Diluted | -1.27 | 0.43 | -1.23 | -2.91 |
| Weighted Avg Shares Out | 54,038 | 52,703 | 37,585 | 30,896 |
| Weighted Avg Shares Out Dil | 54,038 | 52,989 | 37,585 | 30,896 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,735 | $3,937 | $1,106 | $346 |
| Interest Expense | $0 | $0 | $2,605 | $1,940 |
| Depreciation & Amortization | $2 | $367 | $869 | $646 |
| EBITDA | -$72,482 | $27,154 | -$42,941 | -$87,170 |
| % Margin | -151.1% | 26.2% | -88.4% | -2,839.4% |